SEATTLE, Oct. 29, 2020 /PRNewswire/ -- AGC Biologics,
a leading global biopharmaceutical Contract Development and
Manufacturing Organization (CDMO), announced that its partnership
with Horizon Therapeutics plc (Nasdaq: HZNP) is expanding to
produce Horizon's Thyroid Eye Disease (TED) treatment, TEPEZZA, at
AGC's new facility in Boulder, CO.
The state-of-the-art facility includes two 20,000L stainless steel
mammalian bioreactors which AGC is offering to customers who need
very high-volume commercial production.
"We have partnered with AGC on TEPEZZA production for more than
three years and have seen excellent collaboration between our
technical teams, which has resulted in rapid process transfer and
an efficient launch," says Michael
DesJardin, Executive Vice President, Technical Operations
and Corporate Quality, Horizon. "AGC has a deep understanding of
TEPEZZA and we look forward to expanding our partnership."
AGC and Horizon began partnering in 2017 and there are ongoing
projects at AGC's Copenhagen and
Seattle facilities. Horizon will
now be AGC's first client that will have a product manufactured at
the new site in Boulder. The
facility is well equipped for the production of TEPEZZA. Following
approval, it is expected that the facility will produce the
majority of the TEPEZZA supply.
"We are extremely pleased to expand our strategic partnership
with Horizon by leveraging the large-scale stainless steel capacity
at our new facility in Boulder,"
says AGC Biologics Chief Business Officer Mark Womack. "Our globally aligned network is
equipped and ready to continue supplying TEPEZZA to the
market."
About Horizon Therapeutics:
Horizon is focused on
researching, developing and commercializing medicines that address
critical needs for people impacted by rare and rheumatic
diseases. Our pipeline is purposeful: we apply scientific
expertise and courage to bring clinically meaningful therapies to
patients. We believe science and compassion must work
together to transform lives. For more information on how we
go to incredible lengths to impact lives, please visit
www.horizontherapeutics.com.
About AGC Biologics:
AGC Biologics is a leading global
biopharmaceutical Contract Development and Manufacturing
Organization (CDMO) with a strong commitment to deliver the highest
standard of service as we work side-by-side with our clients and
partners, every step of the way. We provide world-class development
and manufacture of mammalian and microbial-based therapeutic
proteins, plasmid DNA (pDNA), viral vectors and genetically
engineered cells. Our global network spans the U.S., Europe and Asia, with cGMP-compliant facilities in
Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan,
Italy; and Chiba, Japan and
we currently employ more than 1,600 employees worldwide. Our
commitment to continuous innovation fosters the technical
creativity to solve our clients' most complex challenges, including
specialization in fast-track projects and rare diseases. AGC
Biologics is the partner of choice. To learn more, visit
www.agcbio.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/agc-biologics-and-horizon-therapeutics-plc-expand-partnership-301163318.html
SOURCE AGC Biologics